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We recently showed that Xq26.3 microduplications cause X-linked acrogigantism 
(X-LAG). X-LAG patients mainly present with growth hormone and prolactin-secreting 
adenomas and share a minimal duplicated region containing at least four genes. GPR101 
was the only gene highly expressed in their pituitary lesions, but little is known about 
its expression patterns. In this work, GPR101 transcripts were characterized in human 
tissues by 5ʹ-Rapid Amplification of cDNA Ends (RACE) and RNAseq, while the putative 
promoter was bioinformatically predicted. We investigated GPR101 mRNA and protein 
expression by RT-quantitative PCR (qPCR), whole-mount in situ hybridization, and 
immunostaining, in human, rhesus monkey, rat and zebrafish. We identified four GPR101 
isoforms characterized by different 5ʹ-untranslated regions (UTRs) and a common 6.1 kb 
long 3ʹUTR. GPR101 expression was very low or absent in almost all adult human tissues 
examined, except for specific brain regions. Strong GPR101 staining was observed in 
human fetal pituitary and during adolescence, whereas very weak/absent expression 
was detected during childhood and adult life. In contrast to humans, adult monkey and 
rat pituitaries expressed GPR101, but in different cell types. Gpr101 is expressed in the 
brain and pituitary during rat and zebrafish development; in rat pituitary, Gpr101 is 
expressed only after birth and shows sexual dimorphism. This study shows that different 
GPR101 transcripts exist and that the brain is the major site of GPR101 expression across 
different species, although divergent species- and temporal-specific expression patterns 
are evident. These findings suggest an important role for GPR101 in brain and pituitary 

























http://jme.endocrinology-journals.org © 2016 Society for Endocrinology
Printed in Great Britain























Research g trivellin and others GPR101 expression
Introduction
X-linked acrogigantism (X-LAG) is a recently discovered 
syndrome characterized by early childhood-onset 
gigantism due to Xq26.3 microduplications (Trivellin 
et  al. 2014). We have shown that microduplications in 
X-LAG patients can occur constitutionally or as somatic 
mosaicism (Daly et al. 2016b) as was recently confirmed 
elsewhere (Iacovazzo et al. 2016, Rodd et al. 2016). Patients 
with X-LAG present with mixed growth hormone (GH) 
and prolactin (PRL)-secreting pituitary macroadenomas 
and/or hyperplasia before 5 years of age (Beckers et  al. 
2015). We have previously shown that the smallest 
common duplicated region shared by all patients is about 
500 kb long and contains four OMIM genes, of which only 
an orphan G protein-coupled receptor (GPCR) named 
GPR101 (OMIM# 300393) is highly expressed in pituitary 
tumor tissue. Functional studies showed that GPR101 
duplication is the likely cause of X-LAG (Trivellin et  al. 
2014). The very recent finding of a patient harbouring 
a duplication of only the GPR101 gene supports our 
determination of its causative role in X-LAG (Iacovazzo 
et al. 2016).
GPR101 belongs to the class A rhodopsin superfamily 
of GPCRs (Kakarala & Jamil 2014). Phylogenetic analysis 
showed that it is most similar to another orphan GPCR 
named GPR161 (Mukhopadhyay et  al. 2013). Both 
GPCRs are closely related to the adrenergic and serotonin 
receptors, but share only about 30% sequence identity 
in their transmembrane regions (Lee et  al. 2001). So 
far, very little is known regarding which tissues express 
GPR101, especially in humans. We and others have 
previously shown that Gpr101 is highly expressed in the 
hypothalamus in rodents, where it seems to play a role 
in hypothalamic control of energy homeostasis (Lee et al. 
2001, Bates et al. 2006, Nilaweera et al. 2007, 2008, Regard 
et al. 2008, Trivellin et al. 2014). Interestingly, an increase 
in Gpr101 mRNA expression in the rat hypothalamus 
was seen after puberty and from late pregnancy to late 
lactation suggesting that the receptor may also play a 
role in physiological processes associated with pregnancy, 
lactation and reproduction (Nilaweera et  al. 2008) 
(E Beadle, D O Larco, A Vana, M Cho-Clark and T J Wu, 
personal communication). On the contrary, few cells seem 
to express GPR101 in the adult human hypothalamus. 
Normal pituitary and GH-secreting tumors without 
the Xq26.3 duplication also show relatively scarce or 
negligible GPR101 expression (Trivellin et al. 2014).
The complete structure of the human GPR101 gene 
is unknown as only the coding sequence (CDS) 
has been characterized to date (NM_054021.1/
ENST00000298110.1). The putative GPR101 transcript 
is 1527 base pairs (bp) long and consists of one protein-
coding exon. The structure of the Gpr101 gene has been 
better characterized in mouse (NM_001033360.3) and 
rat (NM_001108258.1) and in both species it consists 
of two exons, of which only exon 2 is protein-coding. 
In zebrafish, a gpr101 ortholog has been predicted and 
annotated (ENSDARG00000039218). The human GPR101 
gene shares 80, 79 and 55% similarity with the mouse, rat 
and zebrafish orthologs, respectively (http://www.ncbi.
nlm.nih.gov/homologene/).
We undertook this study to better characterize 
GPR101 expression across different species, and to define 
the structure of the human gene.
Materials and methods
Animal care and use
All animal experiments were approved by the National 
Institute of Child Health and Human Development 
(NICHD) Animal Care and Use Committee (ACUC).
In silico analyses
Alignment of the mouse Gpr101 mRNA (NM_001033360.3) 
to the human genome (GRCh37/h19 assembly) and of the 
human putative GPR101 promoter region to the mouse 
genome (GRCm38/mm10) was performed with the BLAST 
tool (http://blast.ncbi.nlm.nih.gov/Blast.cgi) using the 
discontiguous megablast algorithm. Analysis of the human 
putative GPR101 promoter region was also performed 
with other three software packages: MPromDb (http://
mpromdb.wistar.upenn.edu/search), the University of 
California, Santa Cruz (UCSC) genome browser track 
annotating transcription factors (TFs) binding sites assayed 
by ChIP-seq (TF ChIP-seq (161 factors) from ENCODE with 
Factorbook Motifs), and the MatInspector tool from the 
Genomatix Software Suite (http://www.genomatix.de/). 
Genomatix results were filtered by vertebrate elements, 
location (only sites located within or spanning the 
conserved human-mouse regions were considered), a 
matrix similarity threshold of 0.85, and strand (only for 
TATA box elements, since true positives are considered 
those in the same orientation of the gene).
RNAseq and rapid amplification of cDNA ends
Total RNA was extracted from two female patients with 
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Table 1 TaqMan assays used to specifically detect the four different GPR101 isoforms.
TaqMan assay Primer/probe Sequence (5ʹ–3ʹ) Assay length (bp)
Isoform 1 Forward AAGAATCAGGAAACGGTGAGACA 112
Reverse CTGTTTACGACCGTCAGTTTCTGT
Probe CGAGAGACACTGGAGAAG
Isoform 2 Forward TGCCTCTCAGAGCTTGCAG 227
Reverse GCACAGACCGCACTCAGT
Probe CAGCAGCAACAGCATAGGC
Isoform 3 Forward CGGCAAAATAAAGTCCACAGGG 141
Reverse GAGACAGGTTGCAGGCTCAG
Probe ACCAAGCATAGGCACTGAGT
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(Trivellin et al. 2014, Beckers et al. 2015), and from HEK293 
cells, as described previously (Trivellin et al. 2014). RNAseq 
analysis was performed by Zymo Research in pituitary 
tumor RNA samples from both X-LAG patients. Briefly, 
HiSeq 50 × 2 bp paired-end reads from RNAseq samples 
first went through quality control steps by trimming 
adaptors and low quality bases (q score < 20) and were 
then analyzed using the Cufflinks software (v2.2.0) for 
transcript assembly and differential expression. Default 
parameters were used unless otherwise specified. BAM 
files were visualized with IGV v.2.3.61.
To precisely characterize the 5ʹ-untranslated region 
(UTR) of GPR101, the SMARTer Rapid Amplification of 
cDNA Ends (RACE) cDNA Amplification Kit (Clontech 
Laboratories) was employed, following the manufacturer’s 
instructions. The following reverse gene-specific primer 
(GSP) located within the CDS of GPR101 was used for 
5ʹ-RACE: 5ʹ-CCCCAGCCGTAGAGTGGAGGAGTGC-3ʹ. 
Samples that were analyzed by 5ʹ-RACE include matched 
RNA samples isolated from lymphocytes and the pituitary 
tumor of an X-LAG patient, and RNA isolated from 
HEK293 cells. The identity of the 5ʹ-RACE products 
was confirmed by sequencing using the following 
primers: Isoform 1F 5ʹ-GGGCCATGGGAAAAAGATGTA
GAGA-3ʹ, Isoform 2F 5ʹ-CGCTGCCTCTCAGAGCTT-3ʹ, 
Isoform 3F 5ʹ-TTTTGCCTTTCTCCCCAGCT-3ʹ, Isoform 
4F 5ʹ-CCAACGAGAGAGTGCACACA-3ʹ, Isoforms 
1-4commonR 5ʹ-GCACGGTTGAGCGGATGAT-3ʹ. The 
identity of the entire 3ʹUTR of GPR101 determined by 
RNAseq was confirmed by using the following primer 
pairs: 3ʹUTR_1F 5ʹ-GGTGGGACTGAAGGCAAGAT-3ʹ and 
3ʹUTR_1R 5ʹ-ATTCTGCCTTCCTTGCTCCC-3ʹ, 3ʹUTR_2F 
5ʹ-AGAAGTGGCCTAAGTCCTACAA-3ʹ and 3ʹUTR_2R 
5ʹ-GGGAATCTCAGTGCCCTTGA-3ʹ, 3ʹUTR_3F 5ʹ-CCCCT 
TCAAAGTGTATCAGAGA-3ʹ and 3ʹUTR_3R 5ʹ-CTGGCAC 
TTTTCCTTACCTGT-3ʹ, 3ʹUTR_4F 5ʹ-TGGAAGCAGGGAA 
GGAGAGA-3ʹ and 3ʹUTR_4R 5ʹ-AGTGACCTGGCAATC 
TGTGG-3ʹ, 3ʹUTR_5F 5ʹ-GTCAAATGCCCAGCTTGCTT-3ʹ 
and 3ʹUTR_5R 5ʹ-ACCGTAGCTGTGACCCCATA-3ʹ, 
3ʹUTR_6F 5ʹ-CCCCTTTGGTTGGTTGTCTG-3ʹ and 
3ʹUTR_6R 5ʹ-TCAATTTCTCCGCATTTCCCA-3ʹ.
There are some intrinsic limitations in the techniques 
employed: RNAseq experiments are limited by the 
number of reads covering specific regions in each sample 
making thus difficult to exactly determine the boundaries 
of transcripts. RACE products can be incomplete due to 
the premature termination of first-strand cDNA synthesis 
caused by pausing of the reverse transcriptase enzyme, 
especially for long RNAs (SMARTer RACE 5ʹ/3ʹ Kit User 
Manual, Clontech). To describe the beginning of each 
alternative 5ʹUTR exon 1 and the end of the 3ʹUTR we 
decided to adopt a conservative approach and to report 
in the ‘Results’ section genomic coordinates that were 
verified by Sanger sequencing. Based on the location of 
the primers used for sequencing it is, therefore, possible 
that actual transcripts may vary by a few base pairs.
mRNA expression analysis
The expression levels of human GPR101 were measured 
by RT-quantitative PCR (qPCR) in a Human Normal cDNA 
Array containing 48 samples covering all major human 
normal tissues (HMRT103, Origene, Rockville, MD, USA). 
The TaqMan system using a ready-made probe-primer kit 
supplied from Applied Biosystems was used (Assay ID: 
Hs00369662_s1). This assay is located within GPR101 
CDS and can detect all four isoforms. To determine the 
expression levels of each individual transcript, isoform-
specific TaqMan assays were designed using the Primers 
Express v3.0 software (Applied Biosystems) (Table 1).
Total RNA was reverse transcribed to cDNA using the 
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manufacturer’s protocols. The following samples were 
analyzed: pituitary tumors and lymphocytes of both 
X-LAG patients, lymphocytes of the unaffected parents 
of one X-LAG patient, two GH-secreting tumors without 
Xq26.3 microduplication, four normal pituitary glands, 
and HEK293 cells.
Human ACTB (Beta Actin, Applied Biosystems, 
4326315E) was used as endogenous control in all 
reactions. TaqMan assays were performed according 
to manufacturer’s protocol (Applied Biosystems) and 
analyzed using the ΔΔCt method, as described previously 
(Trivellin et al. 2014).
Total RNA was extracted from individual rat anterior 
pituitary glands using an RNeasy Plus Mini Kit (Qiagen) 
and reverse transcribed with a Transcriptor First Stand 
cDNA Synthesis Kit (Roche Applied Science). The 
expression levels of rat Gpr101 were measured by qPCR 
using the TaqMan system (Assay ID: Rn02084654_s1, 
Applied Biosystems) and normalized on Gapdh 
expression, as described previously (Bjelobaba 
et al. 2015).
Total RNA extracted from WT EK zebrafish embryos 
at different developmental stages was a generous gift 
of Dr Sadie Bergeron (National Institutes of Health 
(NIH)). One mcirogram of RNA was treated with 
DNase I (Applied Biosystems) to remove genomic DNA 
contamination and then reverse transcribed to cDNA 
using the Superscript III Kit (Applied Biosystems) 
according to the manufacturer’s protocols. The 
expression levels of zebrafish gpr101 were measured 
by RT-PCR using the following primers: forward: 
TTCGTGCTCAACTTGCTCCT, reverse: CGCAGACA 
CTAGGGCAGAAT. Beta-actin (bactin1) was used as 
endogenous control (McCurley & Callard 2008).
Zebrafish embryo production
WT EK zebrafish were used for all embryo production. All 
embryos were staged according to Kimmel et al. (1995).
Whole-mount in situ hybridization
A 1438 bp genomic sequence corresponding to the 
entire zebrafish gpr101 gene (ENSDARG00000039218) 
was cloned into the pCS2 vector and a DIG-labeled RNA 
antisense probe was synthesized by in vitro transcription 
(DIG RNA Labeling Kit (SP6/T7), Sigma-Aldrich) 
following manufacturer’s protocol. The gh1 antisense 
probe was a generous gift of Dr Alberto Rissone (NIH). 
Whole-mount in situ hybridization (WISH) was then 
performed in WT EK embryos collected at different 
stages of development as described previously (Thisse 
& Thisse 2008). Staining with sense probes for both 
gpr101 and gh1 showed no staining, as expected (data 
not shown). Double WISH/immunofluorescence was 
performed as described previously (Barresi et al. 2005). 
The following antibodies were used: rabbit polyclonal 
anti-PRL (dilution 1:500, generous gift of Dr Akiyoshi 
Takahashi, Kitasato University, Japan), mouse 
monoclonal antityrosine hydroxylase (dilution 1:400, 
MAB318, clone LNC1, EMD Millipore) and appropriate 
rabbit/mouse secondary Alexa Fluor 488 (dilution 
1:400, Thermo Fisher Scientific). Stained embryos were 
cleared in glycerol and photographed.
Tissue collection and immunostaining
Normal human pituitary tissues were collected during 
autopsy. Changes in cell density in the fetal pituitary 
were studied according to gestational age and location 
in the lateral or medial portions of the gland. There 
were 18 fetal pituitary samples from gestational ages 
ranging from 12 to 38 weeks. Of these, seven pituitary 
samples could be analyzed completely in lateral and 
medial portions on both sides of the developing gland. 
Formalin-fixed paraffin-embedded samples of whole 
fetal pituitaries preserved at autopsy were sectioned 
using standard techniques. All paraffin-embedded slides 
were submitted to de-parafinization, rehydration and 
antigen retrieval for 30 min in citrate buffer solution 
(pH 6.0). All slides were incubated with 10% normal 
donkey serum (NDS) for 1 h for blocking of nonspecific 
binding, and afterward incubated with the following 
primary antibodies: rabbit anti-GPR101 (dilution 1:500; 
SAB4503289, Sigma-Aldrich), goat anti-GH (dilution 
1:100, sc-10364; Santa Cruz Biotechnology) overnight at 
4°C. All slides were incubated for 1–2 h with the following 
secondary antibodies: donkey antirabbit 555 (A-31572, 
Applied Biosystems) and donkey antigoat 488 (A-11055, 
Applied Biosystems), both at 1:500 dilution. Prolong 
gold mounting media with DAPI (P36934, Applied 
Biosystems) was used to set the slides. As negative control, 
a specimen’s section was incubated under identical 
conditions without primary antibody. Fluorescence was 
analyzed with a Leica AF6000 microscope (Leica) at a 
63× magnification with fixed time of exposure for all 
samples. Subsequently, images were deconvoluted with 
the supplied Leica image processing software (Leica).
Male and female rat and female Rhesus monkey 
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Figure 1
In silico analyses to predict human GPR101 promoter and untranslated regions. (A) This panel shows the human GPR101 aligned with mouse and rat 
Gpr101. The track displaying nonhuman RefSeq genes follows the display conventions for gene prediction tracks. The color shading indicates the level of 
review the RefSeq record has undergone: predicted (light), provisional (medium), reviewed (dark). The RNAs were aligned against the human genome 
using Blat. A track with the predicted CpG islands is also shown underneath. The number on the left of each island represents the CpG count. (B) The 
mouse Gpr101 mRNA was BLASTed to the human genome to determine the predicted UTRs of GPR101. The alignment predicted a 215 bp 5ʹUTR located 
about 2 kb upstream of the start codon and a splicing event in the 3ʹUTR. (C and D) Analysis of the putative human GPR101 promoter region; 5 kb 
upstream of the predicted GPR101 TSS were aligned to the mouse genome (C). The alignment returned four regions which were further analyzed by 
MPromDb (orange bar), the UCSC genome browser track annotating TF binding sites assayed by ChIP-seq (gray bars) and Genomatix (yellow bars) (D). 
The identity of the predicted TFs is shown in Supplementary Fig. 1B and C. The location of the previously predicted CpG island by CpG Island Searcher 














































http://jme.endocrinology-journals.org © 2016 Society for Endocrinology
Printed in Great Britain
Published by Bioscientifica Ltd.
102 57 2:
48 h. Tissue was then processed for paraffin embedding. 
Five-micrometer-thick coronal sections of the pituitary 
tissues were deparaffinized and the heat-induced antigen 
retrieval was done in a microwave for 5 min with 10 mM 
citrate buffer (pH 6). The rabbit polyclonal anti-GPR101 
(SAB4503289, Sigma-Aldrich) was applied in 2 µg/mL 
dilution overnight at 4°C. Immunofluorescence staining 
was performed using a Tyramide signal amplification 
kit (T20922, Invitrogen) with horseradish peroxidase-
goat antirabbit IgG and Alexa fluor 488 tyramide, 
according to the manufacturer’s instructions. Tissue 
was further processed for the second staining with 
another rabbit polyclonal antibody; to avoid false-
positive overlapping of signals, microwave treatment 
was used (Toth & Mezey 2007) as described previously 
(Li et  al. 2011). Rabbit antirat PRL, LHβ, ACTH, TSHβ, 
GH antisera were obtained from Dr AF Parlow (National 
Institute of Diabetes and Digestive and Kidney Diseases 
(NIDDK), National Hormone and Peptide Program, 
Torrance, CA, USA) and used at a 1:400 dilution. For 
monkey tissue, rabbit anti-GH was obtained from DAKO 
(Dako North America, Inc, Carpinteria, CA, USA), 1:400 
dilution. Donkey antirabbit Alexa fluor 647 was then 
applied at a 1:400 dilution for 2 h. The sections were 
mounted in Mowiol and visualized under an inverted 
confocal microscope (Zeiss LSM 510). The same linear 
adjustments for brightness, contrast and color balance 
have been applied with Adobe Photoshop CS6 to each 
entire image.
Statistical analysis
For the mRNA expression experiments in rat pituitary 
tissue, a statistical analysis was performed with StatsDirect 
software (Addison-Wesley-Longman, Cambridge, UK). 
Data are presented as the mean ± s.e.m. values from 6 to 37 
pituitaries per group (Bjelobaba et al. 2015). Comparisons 
were calculated using a two-tailed Student’s t-test for 
Figure 2
Structure and expression of GPR101 transcripts. (A) Four isoforms were observed in the analyzed samples by both 5ʹ-RACE and RNAseq. All isoforms 
shared a common 3ʹUTR, while they differ for the 5ʹUTR. The coding sequence (CDS) is represented as a dark gray box, the UTRs as a smaller light gray 
box and the intron as a black line. (B) Relative expression of the four isoforms assessed by qPCR in a pituitary tumor harboring an Xq26.3 
microduplication. Isoform 1 is expressed at much higher levels than the other isoforms. (C) Isoform 1 expression in different tissues. The relative 
expression of isoform 1 was determined by qPCR in the following samples: pituitary tumor and lymphocytes of an X-LAG patient, lymphocytes of her 
unaffected parents, normal pituitary, GH-secreting tumor without Xq26.3 microduplication, HEK293 cells. Isoform 1 expression was detected only in 
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Figure 3
GPR101 mRNA expression in normal adult human tissues. (A) GPR101 expression in a panel of 48 different human tissues. (B) GPR101 expression in a 
panel of 24 human brain regions. The highest GPR101 expression levels were observed in the nucleus accumbens. All values are relative and were 
normalized on ACTB expression. The dotted lines represent the average expression in all tissues analyzed in each cDNA panel.
unpaired data. The data were considered to be significant 
when P < 0.05.
Results
In silico analysis to predict the promoter and 
untranslated regions of human GPR101
For both mouse and rat Gpr101 orthologs, the UTRs 
have been characterized, whereas for the human GPR101 
gene only the CDS, located on the reverse strand of 
chromosome X at 136,112,307-136,113,833 (hg19 
assembly), has been characterized. Since the mouse 
Gpr101 RefSeq is reported as ‘Validated’, while the rat 
RefSeq status is ‘Provisional’, we decided to BLAST the 
mouse Gpr101 mRNA (NM_001033360.3) to the human 
genome. This alignment resulted in 74% identity and 83% 
coverage. Three regions were aligned with the human 
genome, predicting the UTRs of GPR101: region 1 (215 bp 
from 136,115,961 to 136,116,175), which includes the 
putative 5ʹUTR; region 2 (2380 bp from 136,111,456 to 
136,113,835), which includes the CDS and part of the 
putative 3ʹUTR; and region 3 (1901 bp from 136,106,090 
to 136,107,990), which includes most of the putative 
3ʹUTR (Fig. 1A). This analysis suggests that a splicing event 
occurs within the 3ʹUTR. The prediction of a long 3ʹUTR is 
also supported by the conservation of the DNA sequence 
in vertebrates (Supplementary Fig.  1A, see section on 
supplementary data given at the end of this article).
We then analyzed the putative human GPR101 
promoter region by selecting 5 kb upstream of the 
predicted transcription start site (TSS) and aligning it 
to the mouse genome to look for conserved regions 
that are likely to harbor important transcriptional 
sites. This alignment resulted in 78% identity and 21% 
coverage. From this analysis, four regions were aligned 
with the human genome (Fig.  1B). We then further 
analyzed this 5 kb region by employing three different 
software programs: MPromDb (a mammalian promoter 
database), the UCSC genome browser track annotating 
TF binding sites assayed by ChIP-seq and Genomatix. 
MPromDb predicted a 1097 bp promoter region located 
at 136,116,010–136,117,106. The location of the TF 
binding sites predicted with the other two software 
packages are shown in Fig.  1B and Supplementary 
Fig.  1B and C. Taken together, these in silico analyses 
showed that the putative GPR101 promoter is likely 
located within 2 kb upstream of the predicted TSS, 
with the most important sites present within the 
first 1000 bp.
In vitro characterization of GPR101 UTRs
To confirm the in silico analysis, we characterized in vitro 
the UTRs of GPR101. Four GPR101 isoforms were identified 
in different human mRNA samples by the combination of 
5ʹ-RACE and RNAseq (Fig. 2A and Supplementary Fig. 2). 
The four isoforms are the result of alternative splicing 
at the 5’UTR, whereas they share a common 3’UTR that 
extends for 6.1 kb after the stop codon, until position 
136,106,207.
Isoform 1 consists of a single exon. The 5ʹUTR extends 
for 1300 bp upstream of the start codon (136,113,834–
136,115,136). This isoform was observed in HEK293 cells 
and in all pituitary samples, albeit at different expression 
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HEK293 cells was at the limit of detection by qPCR, but 
we were nonetheless able to identify it in these cells by 
5ʹ-RACE PCR (Fig. 2C).
Isoform 2 consists of two exons and was observed by 
RNAseq and 5ʹ-RACE PCR in the pituitary tumors of the 
two X-LAG patients and in HEK293 cells. The first exon is 
entirely noncoding and extends for 215 bp (136,115,961-
136,116,175), while the second exon consists of 92 
noncoding bp upstream of the start codon (136,113,834-
136,113,925) and the 1527 bp CDS. The two exons are 
separated by a 2035 bp long intron.
Isoforms 3 and 4 also consist of two exons and differ 
from isoform 2 at exon 1. In isoform 3, exon 1 extends for 
302 bp (136,115,139–136,115,440) and is separated from 
exon 2 by a 1213 bp long intron; in isoform 4, exon 1 
extends for 295 bp (136,114,730–136,115,024) and is 
separated from exon 2 by an 804 bp long intron. Both 
isoforms were found in the pituitary tumors of the two 
X-LAG patients; isoform 4 was also observed in HEK293 
cells but only by 5ʹ-RACE PCR.
While we were able to detect isoforms 2, 3 and 4 
by 5ʹ-RACE PCR in different cells, their expression was 
detectable by qPCR only in the pituitary tumors of X-LAG 
patients, albeit at very low levels (Fig. 2B). Both intronic 
sequences of isoforms 2, 3 and 4 present classic donor and 
acceptor splice sites.
GPR101 mRNA expression in adult human tissues
To determine which tissues express GPR101 in humans, 
we performed qPCR in a panel of 48 normal adult 
tissues. GPR101 was generally expressed at low levels in 
all tissues analyzed (Fig.  3A). As Gpr101 was previously 
shown to be expressed predominantly in the brain in 
rodents, we analyzed GPR101 messenger levels in a panel 
of 24 different human brain regions. In adult humans, 
the highest GPR101 levels were observed in the nucleus 
accumbens. Other areas that showed relatively high 
expression were the medulla and the occipital lobe 
(Fig. 3B).
Figure 4
Labeling of GPR101 in the anterior pituitary 
gland of female rhesus monkey (A, B, C, D, E and 
F) and rat (G, H and I). (A) Preincubation of 
GPR101 antibody with blocking peptide, resulted 
in no staining. (B) Punctuate GPR101 (green) 
labeling could not be attributed to somatotrophs 
(red). (C) GPR101 (green) is expressed by 
LHβ-positive cells (red). (D, E and F) High 
magnification images showing membranous and 
cytoplasmic distribution of GPR101 in monkey 
gonadotrophs, excluding nucleus. (G, H and I) 
GPR101 (green) is expressed by subpopulation of 
rat somatotrophs (red), as indicated by arrows. 
Scale bars: A, B, C and D: 20 µm; E: 10 µm. A full 
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Figure 5
Human pituitary gland staining characteristics for GPR101. Panel A shows an H&E stain transverse section of an entire pituitary gland from a 14-week-old fetus 
at low magnification (50×). The medial (M) and lateral (L) portions of the gland are highlighted. Panel B shows GPR101 staining (brown immunopositivity 
highlighted) in the lateral portion of a 14-week-old fetal pituitary at higher magnification (400×). Immunopositivity is localized to the cytoplasm and is 
negative in the nuclei. The different staining intensities for GPR101 at 24 weeks in the lateral (Panel C) and medial (Panel D) portions of the fetal pituitary can 
be seen (400×). Some positivity for GPR101 in capillaries can also be seen. The increasing GPR101 staining intensity in the lateral portion of the fetal pituitary is 
illustrated in Panel E at 34 weeks, where very high density is seen (400×). Panels F–I show GPR101 (red) and GH (green) immunofluorescence staining in the 
anterior pituitary during postnatal life. Almost absent GPR101 expression was seen in a 2-year-old female child (F) and in a 21-year-old male (I). Several 
GPR101-positive cells were present in two males aged 10 (G) and 17 (H) years old. Very little co-localization of GPR101 with GH was seen in panels G and H. 
Nuclei (blue) were counterstained with DAPI. A full colour version of this figure is available at http://dx.doi.org/10.1530/JME-16-0045.
GPR101 expression in the adult anterior pituitary gland 
of other species
We previously reported that GPR101 expression in the 
normal adult human pituitary is very low or absent (Trivellin 
et al. 2014). We confirm here our previous data by extending 
the analysis to further samples (Supplementary Fig.  3). 
To determine if this expression pattern is similar in other 
species, we assessed GPR101 expression in the adult pituitary 
of rhesus monkey and rat. In rhesus monkey pituitary 
tissue sections, GPR101 immunoreactivity was observed 
in gonadotroph cells, whereas all the other hormone-
secreting cells stained negative (Fig. 4A, B, C, D, E and F). 
Immunohistochemical analysis in the rat pituitary showed 
a different expression pattern, with only GH-secreting cells 
expressing GPR101 (Fig. 4G, H, I and Supplementary Fig. 4).
GPR101 expression during development
In order to determine if the expression of GPR101 
can be regulated in a time-dependent manner during 
different stages of human growth, we performed GPR101 
immunostaining in anterior pituitary tissues collected at 
autopsy during fetal development, early childhood and 
adolescence. GPR101-positive cells were absent or seen at 
very low levels in pituitary samples from before 19 weeks 
of gestation (Fig. 5A and B). From 19 to 25 weeks, about 
20–30% of cells were positive for GPR101 (Fig.  5C and 
D). Thereafter, positivity for GPR101 rose steadily from 
nearly 40% positive at 26 weeks to >65% of cells positive 
at 38 weeks of gestation (Fig.  5E). However, studying 
medial and lateral locations separately, we found that 
GPR101 positivity in the medial portions of the pituitary 
remained markedly lower than that of the lateral portions 
throughout the fetal pituitary sample series.
In the pituitary tissue from a 2-year-old male child, 
very few if any GPR101-positive cells were seen (Fig. 5F). 
In contrast, we observed several GPR101-expressing cells 
in two male adolescent subjects aged 10 and 17 years 
old (Fig. 5G and H). As previously noted (Trivellin et al. 
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expression was virtually absent in an adult 21-year-old 
male (Fig. 5I).
We also evaluated GPR101 expression during 
development in other species. GPR101 immunostaining 
in the forebrain of E20 female rat embryos was observed 
in several regions, including accumbens subventricular 
zone, rhinencephalon, striatal neuroepithelium, striatal 
subventricular zone, septum, hippocampus and anterior 
hypothalamus (Fig. 6). No sex differences were observed. 
We did not observe overlapping of GPR101 staining 
with vimentin (data not shown). In the prepubertal 
rat pituitary, Gpr101 mRNA expression showed sexual 
Figure 7
In situ staining for gpr101 during WT zebrafish 
development (lateral view). (A) 1-cell, (B) 8-cell, 
(C) 30% epiboly, (D) bud, (E) 3 somite, (F) 20 
somite, (G) 24hpf, (H) 2dpf, (I) 5dpf. gpr101 
mRNA (blue) is visible from 1-cell to 8-cell stage 
(A, B), probably representing maternal transcripts, 
and then reappears during the bud stage (D), 
approximately 10 hpf. Starting at 2 dpf (H) a 
strong and brain-specific staining is seen. Scale 
bar: 100 μm; dpf, days postfertilization; hpf, hours 
postfertilization. A full colour version of this 
figure is available at http://dx.doi.org/10.1530/
JME-16-0045.
Figure 6
Immunolocalization of GPR101 in coronal sections of rat embryo forebrain. (A) GPR101 immunoreactive cells and processes were pronounced in 
accumbens subventricular zone (SVZ) and rhinencephalic differential field (Rh). (B) Strong GPR101 immunoreactivity was observed in striatal 
neuroepithelium and striatal subventricular zone (SVZ) around lateral ventricle (LV) and striatal differentiating field. GPR101-positive cells and cell 
processes were also observed in the septal area. (C) In more posterior sections, GPR101 immunoreactivity was observed throughout the hippocampus 
and lateral to third ventricle (3V), in the anterior hypothalamus. GPR101-positive cells and processes were also noticed in the amygdaloid differentiating 
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Figure 8
gpr101 expression in the brain of WT Zebrafish embryo. (A) and (B) WISH 
staining for gpr101 and gh1 (purple) in 2 dpf distinct Zebrafish embryos 
(ventral view). gpr101 is strongly expressed in the whole brain region (A), 
while a pituitary-specific staining is visible with the gh1 probe (B). (C) and 
(D) Double WISH/immunofluorescence staining for gpr101 (purple) and a 
pituitary (PRL, green, panel C) and hypothalamic marker (tyrosine 
hydroxylase (TH) specific for diencephalic dopaminergic neurons, green, 
panel D) in a 2 dpf Zebrafish embryo (ventral view). gpr101 staining 
overlaps with the location of pituitary and hypothalamic neurons. The 
qualitatively different aspect of gpr101 staining in panels C and D is due 
to the different focal planes selected for PRL and TH. Scale bar: 50 μm 
applies to all panels. A full colour version of this figure is available at 
http://dx.doi.org/10.1530/JME-16-0045.
dimorphism during the first 3 weeks of life, with higher 
expression levels in females than males (Supplementary 
Fig. 5). An expression pattern similar to that observed in 
adult rat pituitary was also seen in prepubertal pituitary 
tissue by immunostaining (data not shown).
In the developing zebrafish embryo, we performed 
WISH using a gpr101-specific probe to determine at 
what stages and in which anatomical regions gpr101 
is expressed. Transcripts of gpr101 showed a bimodal 
temporal expression pattern, with early, and likely 
maternal, messenger RNA levels waning during very 
early stages, then rising from the bud stage through 
2 dpf, and remaining constant through the remainder of 
embryonic development (Fig. 7). This expression pattern 
was recapitulated when we measured gpr101 mRNA 
expression by RT-CR (Supplementary Fig.  6). Starting at 
2 dpf, a strong and brain-specific staining was observed 
(Figs 7 and 8), overlapping with the location of pituitary 
and hypothalamus (Fig. 8).
Discussion
GPR101 is an orphan GPCR that is duplicated in patients 
with X-LAG. High GPR101 expression was observed in 
patients’ pituitary tumor tissues, while low expression 
levels were seen in their blood and in normal pituitaries, 
suggesting that GPR101 is the likely cause of the disease 
(Trivellin et  al. 2014). However, very little is known 
regarding GPR101 function, expression in different tissues 
and species, and transcript structure. We undertook this 
study in order to better understand GPR101 physiology 
and how its deregulation might cause X-LAG, and possibly 
other diseases (Tariq et al. 2013). Four GPR101 transcripts 
were identified. These transcripts are characterized by 
alternative splicing at the 5ʹUTR due to different TSSs, 
while they share a common 6.1 kb long 3ʹUTR.
Isoform 1 seems to be the predominant isoform 
in the human pituitary. The higher expression levels 
observed in the pituitary tumors harboring a duplication 
of GPR101 compared with normal pituitary tissue or 
tumors without the duplication suggests that this is the 
isoform that leads to the previously observed GPR101 
overexpression (Trivellin et  al. 2014). The other three 
isoforms are expressed at much lower levels and were 
readily detectable by qPCR only in GPR101-duplicated 
pituitary tumors. These isoforms might, therefore, 
represent minor transcripts, but we cannot exclude that 
they are specifically expressed in other tissues, where they 
might have a biological function. Isoform 3 was identified 
by both techniques only in mRNA isolated from pituitary 
tumors harboring an Xq26.3 microduplication. While it is 
possible that this is a pituitary-specific transcript, we could 
not exclude that this transcript might be generated due 
to the rearranged surrounding genomic region. Interplay 
between the tridimensional organization of the genome 
and the regulation of alternative splicing has indeed been 
previously shown (Curado et al. 2015).
Different approaches support the real nature of the 
identified transcripts. First, the in vitro data matched 
well with the in silico predictions. The predicted 5’UTR 
matches exactly with exon 1 of isoform 2. Moreover, we 
previously showed that GPR101 is predicted to harbor 
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(Trivellin et  al. 2014). Since CpG islands normally lie 
in the promoter region and can extend into the 5ʹUTR 
(Medvedeva et  al. 2010), this result is in line with the 
location of the identified 5’UTR. In addition, the canonical 
splicing sites identified for all alternative intronic regions 
support their bona fide nature. While we did not observe 
a splicing event within the 3ʹUTR as inferred by the 
in silico alignment, the end of the predicted 3ʹUTR 
supports the in vitro observation. Second, concordant 
results were observed between the two techniques used 
for the in vitro characterization, RACE-PCR and RNAseq. 
It would be interesting for future studies to investigate 
the function of the very long 3ʹUTR, which could harbor 
several binding sites for regulatory molecules, such as 
miRNAs or lncRNAs.
Our in silico analyses showed that the putative GPR101 
promoter region likely extends at least until 1 kb upstream 
of isoform 2 TSS (Fig.  1D). Several features suggest that 
the GPR101 promoter is broad and TATA-less, including 
the identification of a putative core promoter element 
associated with TATA-less genes (XCPE1, Supplementary 
Fig.  1C), the high GC content, and the multiple TSSs 
(Carninci et al. 2006, Sandelin et al. 2007, Tokusumi et al. 
2007). A couple of putative TATA boxes were identified 
but their location far away from the TSS (Supplementary 
Fig. 1C) argues against a role in transcription activation. 
A conserved TATA box is indeed usually located around 
30 bp upstream of the TSS (Sandelin et al. 2007). Future 
in vitro studies are necessary to decipher the function 
of the promoter region as well as of possible enhancers, 
which could lead to abnormally high GPR101 expression 
levels when rearranged.
Our analysis of GPR101 expression in adult human 
tissues showed that GPR101 is generally expressed at 
very low levels, with the exception of the brain, where 
relatively high expression was seen in several regions. This 
brain-specific expression correlates well with the in silico 
identification of a CpG-enriched promoter since this type 
of promoter could be advantageous in this organ due to 
its property of fine-tuning gene transcription (Gustincich 
et  al. 2006). We also previously showed that when 
GPR101 is overexpressed, even in the absence of a ligand, 
it exhibits high constitutive activity by strongly activating 
the cAMP pathway (Trivellin et al. 2014). It is, therefore, 
conceivable that GPR101 expression is normally turned 
down or completely switched-off in most tissues, in line 
with our observations.
Within the brain, the highest GPR101 expression 
levels were observed in the nucleus accumbens, a 
region that plays an important role as the reward center 
and where other GPCRs characterized by constitutive 
activity play vital roles (Meye et al. 2014). This finding 
suggests that GPR101 might be involved in the 
regulation of different behaviors, such as food seeking: 
indeed, about a quarter of X-LAG cases presented with 
increased eating/food seeking that accompanied their 
markedly increased statural overgrowth (Beckers et  al. 
2015). Further studies are thus needed to determine if a 
functional link between GPR101, behavior and physical 
growth exists.
The pituitary gland, by responding to hormonal 
signals from the hypothalamus, constitutes an anatomical 
and physiological link between the nervous and the 
endocrine systems to control several key body functions, 
such as somatic growth. In order to gain insight into 
GPR101’s putative role in regulating growth, we decided 
to investigate its expression in the brain and pituitary 
of different species both during and after development. 
GPR101 expression in the adult anterior pituitary gland 
showed remarkable differences among species. While 
GPR101 is expressed at low levels in adult human pituitary, 
GPR101-positive cells were seen in both monkey and rat 
pituitary. However, the cell types expressing the receptor 
differ in those two species. These results suggest that 
GPR101 might have different functions in the pituitary 
of different species during development and in adult life. 
In particular, in normal adult human pituitary, the main 
physiological role of GPR101 might already be finished. 
This is supported by the fact that high GPR101 expression 
was observed in the human pituitary gland during fetal 
development, which suggests that the receptor might 
play an important physiological role in this organ as it 
proliferates and matures. In particular, the observation 
that GPR101 is mainly expressed in the lateral wings of 
the anterior lobe, where the vast majority of GH- and 
PRL-secreting cells reside (Al-Gahtany et al. 2003, Melmed 
et al. 2011), suggests that the receptor might be involved 
in regulating, directly or indirectly, the embryonic 
differentiation of mammosomatotroph cells. Even if no 
causative association can be demonstrated by these data, 
it is interesting to note that in humans this is the stage 
were the maximum rate of growth in length and weight 
is achieved (Bogin 1999). Furthermore, duplication of 
GPR101 in the setting of X-LAG syndrome is associated 
with a specific pituitary pathology related to somatotroph, 
mammosomatotroph and lactotroph cells (Trivellin et al. 
2014). It will be of interest in future studies to further 
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GPR101 duplication in X-LAG syndrome, as we recently 
showed likely hypothalamic GHRH hypersecretion can 
accompany the pituitary pathology in this condition 
(Daly et al. 2016a).
We also investigated GPR101 expression in the 
pituitary during postnatal development. We observed 
very few GPR101-positive cells in normal pituitary tissue 
from a 2-year-old subject. This result seems to be in line 
with the observation that postnatal growth rates start to 
rapidly decelerate during infancy/early childhood (Bogin 
1999, Stevens et al. 2013). We hypothesized that GPR101 
might also play a role during the so-called ‘adolescent 
growth spurt’, a rapid and intense postpubertal increase 
in the rate of growth in height and weight that, among 
all primate species, is observed only in humans (Bogin 
1999, Lui et al. 2015). This growth stage can account for 
up to 15–20% of adult final height (Cousminer et al. 2013) 
and, even if there is considerable variation between 
individuals and populations, begins on average at 
10 years for girls and 12 for boys, and is clearly over by 
18–19 years for girls and 20–22 years for boys (Bogin 
1999, Lui et al. 2015). To test this hypothesis, we assessed 
GPR101 expression in pituitary tissues from adolescent 
individuals, to see if it might increase. We observed 
many GPR101-expressing cells in two male subjects 
aged 10 and 17 years old, whereas practically absent 
expression was seen in a 21-year-old male. These results 
indicate that GPR101 expression appears to increase 
during the adolescent growth spurt and then wanes 
once this growth phase terminates, thus supporting our 
hypothesis. However, we cannot exclude that GPR101 
might also act at a higher (e.g. hypothalamic) level 
as suggested recently (Daly et  al. 2016a). Altogether 
these results suggest that the expression of GPR101 in 
the human pituitary is tightly timed during pre- and 
postnatal development and lead us to speculate that 
the continuously high expression levels observed in the 
tumor tissues of patients with X-LAG compromise this 
fine regulation leading to uncontrolled growth.
GPR101 expression during pre- and postnatal 
development was also assessed in rat and zebrafish 
brain and pituitary. GPR101 was found to be expressed 
in several regions of the fetal rat brain, including the 
hypothalamus, but excluding the pituitary. These results 
are in agreement with what was previously observed 
in the adult rat brain (Bates et  al. 2006). The absence 
of GPR101 expression in fetal rat pituitary could be 
explained by the fact that growth in rodents shows a 
very different course than in humans, with maximum 
growth rate occurring in the early postnatal period 
(Stevens et  al. 2013). Accordingly, GPR101 expression 
in the pituitary was detected only after birth, even if its 
expression levels were generally quite low. We observed 
sexual dimorphism with the highest relative GPR101 
levels observed in 2-week-old females. Interestingly, at 
this point of female development, the highest mRNA 
levels were also observed for Gnrhr, Lhb, Fshb, 
and gonadotroph/thyrotroph-specific  α  subunit (Cga) 
(Bjelobaba et al. 2015). These results lead us to speculate 
that in rodents, in contrast to humans, GPR101’s putative 
role in growth is largely absent after birth. Moreover, 
GPR101-related effects seem to be exerted both in the 
pituitary and in higher brain regions (Bates et  al. 2006, 
Nilaweera et al. 2007, 2008, Regard et al. 2008, Trivellin 
et  al. 2014). In the zebrafish embryo, strong gpr101 
expression was detected in the brain area. It will be 
important for future studies to generate brain region-
specific knockout animals in order to investigate the 
role(s) played by GPR101 during development.
In conclusion, this study shows that different human 
GPR101 transcripts exist and that the brain is the major 
site of GPR101 expression across different species, 
suggesting a conservation of function for this GPCR. 
On the other hand, we also observed species-specific 
expression patterns, especially concerning the pituitary, 
with GPR101 expression being regulated in a cell type- and 
developmental stage-specific manner in different species. 
Altogether, these findings indicate that (i) GPR101 plays an 
important role in both brain and pituitary development 
and (ii) the differences we observed might reflect the very 
different growth, development and maturation patterns 
among species.
Supplementary data
This is linked to the online version of the paper at http://dx.doi.org/10.1530/
JME-16-0045.
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